Therapeutic Advantage of $^{90}$Ytrrium- versus $^{131}$Iodine-labeled PAM4 Antibody in Experimental Pancreatic Cancer\(^1\)

Thomas M. Cardillo,\(^2\) Zhiliang Ying, and David V. Gold


ABSTRACT

Objectives: Radioimmunotherapy studies using $^{131}$I-PAM4 have demonstrated significant antitumor effects in mice bearing human pancreatic cancer xenografts. For several reasons $^{90}$Y has been proposed as a more effective radionuclide for radioimmunotherapy of pancreatic cancer. The present study examined whether one radionuclide was more efficacious than the other in tumor-bearing mice.

Methods: Athymic nude mice bearing CaPan1 xenograft tumors (~1.0 cm\(^3\)) were given increasing doses of either $^{90}$Y-PAM4 or $^{131}$I-PAM4 up to their respective maximal tolerated doses (MTDs (260 and 700 \(\mu\)Ci, respectively)).

Results: $^{90}$Y-PAM4 provided significantly greater growth inhibition than the $^{131}$I-PAM4 ($P < 0.035$). Median survival time for the untreated mice was 6 weeks, whereas median survival times for the $^{131}$I-treated mice and $^{90}$Y-treated mice at their respective MTDs were 17.5 weeks and >26 weeks (the end of the study period), respectively. Within the $^{131}$I-PAM4-treated group, two of eight mice were responders (>50% decrease in tumor size) for a median of 14 weeks. At the end of the study (26 weeks), 1 mouse was alive with no sign of tumor. All of the $^{90}$Y-PAM4-treated mice were responders with a median duration of response of 20 weeks. Six of the seven mice were alive at week 26, with four mice having no evidence of disease.

Conclusions: These data demonstrate the advantage of $^{90}$Y over $^{131}$I as the radionuclide for PAM4-targeted radioimmunotherapy of xenografted pancreatic cancer. Furthermore, the duration and extent of the antitumor response suggest that multiple treatment cycles of $^{90}$Y-PAM4 may provide an effective therapeutic for the control of pancreatic cancer.

Received 1/31/01; revised 6/22/01; accepted 6/22/01.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

\(^1\)Supported in part by NIH Grant CA54425.

\(^2\)To whom requests for reprints should be addressed, at Garden State Cancer Center, 520 Belleville Avenue, Belleville, NJ 07109. Phone: (973) 844-7023; Fax: (973) 844-7020; E-mail: tmc_gscc@hotmail.com.

INTRODUCTION

Pancreatic cancer is one of the most insidious forms of cancer afflicting adults. The 1999 United States estimates of new cancer cases put pancreatic cancer at 9th and 10th among women and men, respectively. However, it is the fourth leading cause of all cancer deaths in both women and men, surpassed only by lung, colorectal, prostate, and breast cancers. Attributable largely to the location and silent growth of the tumor, most patients present at a time when it is too late to undergo any curative treatment. This has translated into a 5-year survival rate of less than 3% (1).

Our laboratory has developed MAbs\(^3\) PAM4 that by immunohistochemistry was found to be reactive with ~85% of pancreatic cancer specimens (2). Except for a weak reaction with the normal gastrointestinal tract, PAM4 was nonreactive with normal tissues, including the pancreas. In preclinical animal studies, radiolabeled PAM4 targeted to human pancreatic tumor xenografts at high concentrations, demonstrating high specificity (3, 4). Experimental RAIT using $^{131}$I-labeled PAM4 was carried out in mice bearing s.c. and/or orthotopic human-derived pancreatic tumors. Tumor growth inhibition and long-term survival were significantly greater than for isotype-matched, non-specific, control and untreated mice. In clinical Phase I trials using the $^{131}$I- or $^{99m}$Tc-labeled PAM4 antibody, scintigraphic evidence of tumors was found in 8 of 10 patients suspected of pancreatic cancer (5, 6). Surgery confirmed pancreatic cancer in the 8 patients. One of the two negative patients was found to have chronic pancreatitis and not pancreatic cancer, and the other negative patient had a poorly differentiated pancreatic cancer that was nonreactive with PAM4 by immunohistochemistry.

Currently, $^{131}$I is the primary radionuclide chosen for RAIT. The major reasons for this are: (a) the labeling methods for $^{131}$I are well defined; (b) it is abundant and inexpensive; and (c) its $\gamma$ emissions allow for the tracing of $in\ viva$ distribution by external camera imaging, and its $\beta$ emissions are good for therapy.

Certain physical properties have been proposed for an ideal radionuclide to be used in RAIT (7). These include a physical half-life ($t_{1/2}$) of 1–3 days, major energy deposition between 0.5 and 30 cell diameters, and single decay-to-ground state. $^{90}$Y is a radiometal that fits these criteria and may, thus, be a better choice than $^{131}$I for RAIT. $^{90}$Y has a greater energy emission than $^{131}$I ($\beta$, $E_{\text{max}} = 2.27 \text{ MeV}$ versus $\beta$, $E_{\text{max}} = 0.81 \text{ MeV}$, respectively) and a shorter half-life ($t_{1/2} = 2.67 \text{ days}$ versus...
$t_{1/2} = 8.06$ days, respectively). In addition, $^{90}$Y will deposit its energy out to 1.81 cm versus only 0.55 cm for $^{131}$I (8). Of particular note, when conjugated to an internalizing antibody, $^{90}$Y will be retained within the tumor cell for longer periods of time than will $^{131}$I (9–12). The residualizing property of radioisotopes such as $^{90}$Y may allow for a higher radiation dose to the tumor than could be achieved by $^{131}$I. Considering the potential advantages of using a residualizing radionuclide, we examined the antitumor efficacy of $^{90}$Y-labeled DOTA-PAM4 for the treatment of pancreatic cancer.

**MATERIALS AND METHODS**

**Experimental Animal Model.** CaPan1, a human pancreatic carcinoma that was obtained as a cell culture from the American Type Culture Collection (Manassas, VA), was established as a solid tumor by s.c. injection of $10^7$ cells into 5-week-old, female athymic nu/nu mice (Taconic, Germantown, NY). Once tumors had grown to $\sim 1$ cm$^3$, they were serially propagated by s.c. injection of 0.2 ml of a 20% (w/v) tumor suspension prepared by mincing the tumors in 0.9% saline with subsequent passage through a 40-mesh wire screen. CaPan1 cells produced moderate-to-well-differentiated tumors. Tumors used in this study were passaged <10 times. Animal studies were approved by the Garden State Cancer Center’s Institutional Animal Care and Use Committee and were performed in accordance with the American Association of Laboratory Animal Care (AALAC), United States Department of Agriculture (USDA), and Department of Health and Human Services (DHHS) regulations.

**$^{131}$I- and $^{125}$I-antibody Radiolabeling.** The purification and characterization of cPAM4 has been described previously (2). Radiolabeling of MAbs with $^{125}$I and $^{131}$I (NEN Life Science Products, Inc., Boston, MA) was performed by the chloramine-T method (13). The specific activity of the radiolabeled antibodies was in the range of 9.88–12.3 μCi/μg. Quality assurance was performed as described previously (3). All of the radiolabeled preparations contained <8% aggregated material and <5% unbound iodine.

**$^{90}$Y- and $^{111}$In-antibody Radiolabeling.** DOTA (Mardocyls, Inc., Richardson, TX) was conjugated to cPAM4 IgG by a previously described method (14). $^{90}$Ytrium chloride (NEN Life Science Products, Inc., Boston, MA) or $^{111}$indium chloride (Iso-Tex Diagnostic, Inc., Friendswood, TX) was added to a reaction vial with DOTA-cPAM4 IgG at a ratio of 5 mCi per mg of cPAM4. The reaction was incubated at 45°C for 15 min and then quenched by removal from the heat source and the addition of 0.1 volume of 100 mM DTPA. This mixture was then incubated at room temperature for 5 min. A volume of 1% human serum albumin in PBS was added to give a final activity concentration of $\sim 1$ mCi/ml for $^{111}$In-labeled and $\sim 5$ mCi/ml for $^{90}$Y-labeled DOTA-cPAM4. The specific activity for the $^{111}$In label was 5.41 μCi/μg with 1.7% unbound material and less than 1% aggregated material. The specific activity for the $^{90}$Y label was 4.49 μCi/μg with 12.9% unbound material and <6% aggregated material. The final labeled antibody product was placed in a dose calibrator (Capintec CRC15R; Ramsey, NJ) and the time and activity recorded.

**Biodistribution Studies.** Tumor volumes were determined by caliper measurements in three dimensions and calculated by length × width × depth. Mice bearing tumors of similar size were placed into groups of at least eight animals per time point. Groups of mice received an i.v. injection of a mixture of $^{125}$I-cPAM4 (10 μCi) and $^{111}$In-DOTA-cPAM4 (25 μCi). The radiolabeled antibody was augmented with unlabeled antibody to ensure that each mouse received a total of 50 μg of antibody. At specific time points, the tumors, as well as various tissues (liver, spleen, kidney, lung, blood, pancreas, and bone), were removed, weighed, and the radioactivity determined in a 2-channel gamma scintillation counter. Data are expressed as %ID/g. Localization indices were calculated by the equation:

$$\frac{\%\text{ID/g of }^{111}\text{In in Tumor}}{\%\text{ID/g }^{111}\text{In in Blood}} + \frac{\%\text{ID/g of }^{125}\text{I in Tumor}}{\%\text{ID/g }^{125}\text{I in Blood}}$$

Radiation dose estimates were calculated from the biodistribution data. The integral of the time-activity curve was computed trapezoidally with the assumption of no activity at zero time (15). Student’s $t$ test was used to assess significant differences.

**Experimental RAIT.** Mice bearing CaPan1 tumors of $\sim 1$ cm$^3$ at the start of the study were used throughout these studies. The MTD of $^{131}$I-labeled and $^{90}$Y-ITC-Bz-DTPA-labeled cPAM4 IgG were previously determined by i.v. administration of increasing doses of $^{131}$I-cPAM4 or increasing doses of $^{90}$Y-ITC-Bz-DTPA-labeled cPAM4 (16). The MTD was defined as that dose of radiolabeled antibody that resulted in all of the mice surviving at least 4 weeks without losing more than 20% of their starting body weight. In mice bearing 1 cm$^3$ CaPan1 tumors, the MTD was found to be 700 μCi for $^{131}$I-labeled cPAM4 and 260 μCi for $^{90}$Y-labeled cPAM4.

In those experiments comparing $^{131}$I versus $^{90}$Y RAIT, tumor-bearing mice received either increasing doses of $^{131}$I-cPAM4 (350, 525, or 700 μCi) or increasing doses of $^{90}$Y-DOTA-cPAM4 (130, 175, 220, or 260 μCi). One group of mice was left untreated as a control. The mice were weighed prior to being injected and then once a week to ensure that their body weight remained more than 80% of starting weight. Measurements for determination of tumor size were likewise performed on a weekly basis.

**Data Analysis.** Statistical analyses of tumor growth data were based on AUC and survival time. Profiles of individual tumor growth were obtained through linear and exponential curve modeling. The $t$ test was used to assess the statistical significance between the two MTD treatment groups, as well as to perform other pair-wise comparisons. As a consequence of incompleteness on some of the growth curves (caused by deaths), statistical comparisons of AUC were performed only up to the time at which the first animal within a group was killed. AUC analyses were supported by statistical comparisons of survival data; in this case, survival was defined as time for a tumor to reach 5 cm$^3$. At the termination of the study (26 weeks), some of the animals had not yet experienced the end point, and their observations were considered as censored. The Mantel-Haenszel log-rank test was then used for comparison of treatment arms.
Advantage of $^{90}$Y-PAM4 Therapy in Pancreatic Cancer

RESULTS

Biodistribution Studies. Athymic nude mice bearing the CaPan1 human pancreatic carcinoma (~1 cm$^3$ at the start of the study) were given both 25 μCi $^{111}$In-DOTA-cPAM4 and 10 μCi $^{125}$I-cPAM4. Groups of mice were killed on days 1, 2, 3, 7, and 14. Tissue uptake of radiolabeled antibodies are presented as the %ID/g of tissue (wet weight) in Fig. 1. Tumor uptake of $^{111}$In-DOTA-cPAM4 was significantly greater than $^{125}$I-cPAM4 at the 2, 3, and 7 day time points ($P < 0.0002$, 0.0004, and 0.0005, respectively). The highest levels of radiolabeled antibody within the tumor occurred on days 2 and 3, with a $1.67 \pm 0.18$- and $1.82 \pm 0.15$-fold higher level of $^{111}$In-radiolabeled over $^{125}$I-radiolabeled cPAM4, respectively. A steady decline of radioisotope was observed within the tumors after day 3 with an effective $t_{1/2}$ of 45 h for $^{111}$In and 112 h for $^{125}$I. Blood clearances were similar for the two isotopes ($t_{1/2} = 22$ h and 32 h for $^{111}$In and $^{125}$I, respectively). Localization ratios ($^{111}$In: $^{125}$I) of $1.56 \pm 0.19$, $1.58 \pm 0.29$, and $1.81 \pm 0.51$ for days 2, 3, and 7, respectively, clearly demonstrated the increased tumor uptake and retention of $^{111}$In-radiolabeled over $^{125}$I-radiolabeled cPAM4. Nontumor tissue uptake and clearance of the radiolabeled antibodies were similar for most tissues except in the liver, spleen, and bone, for which the %ID/g $^{111}$In was significantly higher than for $^{125}$I. Radiation dose estimates were calculated from the time-activity curves of the biodistribution studies (Table 1). At their respective MTDs of 260 μCi for $^{90}$Y-DOTA-cPAM4 and 700 μCi for $^{131}$I-cPAM4 (16), approximately equal radiation doses would be delivered to the tumors. Tumor:blood radiation dose ratios were 3.27 for $^{131}$I-cPAM4 and 4.09 for $^{90}$Y-DOTA-cPAM4.

RAIT Studies. Groups of athymic nude mice bearing CaPan1 tumors of ~1 cm$^3$ were given a single cycle of either $^{90}$Y-DOTA-cPAM4 (130, 175, 220, or 260 μCi) or $^{131}$I-cPAM4 (350, 525, or 700 μCi). Each dose was augmented with unlabeled cPAM4 so that all of the mice received a total of 50 μg of antibody. Overall, the treatments were well tolerated. However, some early deaths did occur with both radionuclides. In the 700-μCi $^{131}$I-cPAM4 group, one of nine mice was found dead at week 3. This mouse had a 19% drop in body weight at week 2 versus only 6 ± 6% for the group as a whole, which suggested a therapy-related cause. Although previous studies determined the MTD to be 700 μCi, we may be too close to the toxic level and may need to use a slightly lower dose in the future. Likewise one of eight mice within the 260-μCi $^{90}$Y-DOTA-cPAM4 group was found dead at week 4. Although therapy itself cannot be ruled out as the cause of death, the mouse lost only 3% of its body weight at the time of death with a body weight loss of only 3 ± 3% for the group as a whole. The nadir for this treatment group (7 ± 4% weight loss) occurred at day 7. The two mice were excluded from data analyses. The nadir for the 700-μCi $^{131}$I-cPAM4-treated group was also reached at day 7 with an 11 ± 4% weight loss. A comparison of weight loss between the two MTD-treated groups approached a significant difference ($P < 0.056$). Both groups of mice recovered by week 4.

Tumor growth curves were generated with statistical analysis of AUC performed up to the time at which an animal within a group was lost because of disease activity. The 350-, 525-, and 700-μCi $^{131}$I-cPAM4-treated groups all had tumors that were significantly smaller than tumors within the untreated group ($P < 0.003$, 0.015, and 0.003, respectively) at week 3, the last day of treatment.
Comparisons of tumor growth inhibition and survival between the various $^{131}$I- and $^{90}$Y-labeled cPAM4 treatment groups

<table>
<thead>
<tr>
<th>Treatment</th>
<th>$n$</th>
<th>Mean size of tumors at nadir (± SD)</th>
<th>Time when nadir reached (wk)</th>
<th>Median survival time (wk)</th>
<th>No. of survivors at wk 26 (disease-free)*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Untreated</td>
<td>10</td>
<td>N/A</td>
<td>N/A</td>
<td>6</td>
<td>1 (1)</td>
</tr>
<tr>
<td>350 μCi $^{131}$I</td>
<td>10</td>
<td>N/A</td>
<td>N/A</td>
<td>13</td>
<td>2 (2)</td>
</tr>
<tr>
<td>525 μCi $^{131}$I</td>
<td>8</td>
<td>N/A</td>
<td>N/A</td>
<td>12</td>
<td>0</td>
</tr>
<tr>
<td>700 μCi $^{131}$I</td>
<td>8</td>
<td>0.61 cm$^3$ (0.24)</td>
<td>7</td>
<td>17.5</td>
<td>1 (1)</td>
</tr>
<tr>
<td>130 μCi $^{90}$Y</td>
<td>8</td>
<td>0.78 cm$^3$ (0.61)</td>
<td>6</td>
<td>16</td>
<td>2 (1)</td>
</tr>
<tr>
<td>175 μCi $^{90}$Y</td>
<td>8</td>
<td>0.33 cm$^3$ (0.40)</td>
<td>7</td>
<td>&gt;26</td>
<td>4 (4)</td>
</tr>
<tr>
<td>220 μCi $^{90}$Y</td>
<td>7</td>
<td>0.10 cm$^3$ (0.07)</td>
<td>9</td>
<td>&gt;26</td>
<td>5 (2)</td>
</tr>
<tr>
<td>260 μCi $^{90}$Y</td>
<td>7</td>
<td>0.19 cm$^3$ (0.13)</td>
<td>10</td>
<td>&gt;26</td>
<td>6 (4)</td>
</tr>
</tbody>
</table>

* At week 26, any surviving mice were humanely sacrificed and examined by necropsy for macroscopic signs of internal metastasis. Any solid mass at the tumor transplant site was removed and examined histologically to confirm the lack of tumor cells.

N/A, the mean tumor sizes for these mice never regressed below the initial tumor sizes.

DISCUSSION

PAM4 is an IgG1 MAb that recognizes the MUC1 mucin expressed by human pancreatic carcinomas (2). In preclinical studies, $^{125}$I-labeled PAM4 targeted pancreatic tumors with high specificity and could achieve high concentrations of radioisotope within these tumors while minimizing radiation dose delivered to nontumor tissues (3, 4). Similar targeting specificity was observed in initial clinical trials (5, 6). In experimental RAIT studies, $^{131}$I-labeled PAM4 was shown to have significant antitumor effects against both s.c. and orthotopic human pancreatic tumor xenografts (4, 7).

Clinical trials of RAIT have met with some success in recent years. Whereas many positive clinical responses have been achieved against lymphomas (18–21), solid tumors have had only mixed results (22–25). Besides the antibody itself, a major factor influencing the efficacy of RAIT is the choice of radionuclide. Many investigators have reported that the use of residualizing radionuclides, such as $^{90}$Y, yields higher concentrations of radioisotope within the tumor, with consequent greater therapeutic effect than can be achieved by use of $^{131}$I (9–12, 26–28). However, others have found that for certain
MAbs and tumor types, $^{131}$I- could be superior to $^{90}$Y-labeled antibodies (29, 30).

We examined the biodistribution of cPAM4 labeled with either $^{111}$In or $^{125}$I in mice bearing s.c. CaPan1 tumors. Similar to what had been reported by others (11, 26–28), we found that, in our tumor model system, there was a 2-fold increase in %ID/g $^{111}$In in the tumor as compared with $^{125}$I. However, there was also greater uptake in the liver, spleen, and bone. The uptake in the liver and spleen was not an unexpected outcome, because both these organs are the most active in IgG catabolism (31) and as a residualizing radionuclide, $^{111}$In would be retained longer in these tissues than would be the $^{125}$I. It should be noted that at the MTD for $^{90}$Y-DOTA-cPAM4, the absorbed radiation dose for the liver (1660 cGy) would still be well below the reported toxic level of 3000 cGy in mice (32). The other tissue of interest, in which free $^{111}$In and $^{90}$Y can accumulate, is the bone (33). This is an important consideration, because it adds to the overall radiation dose delivered to the bone marrow, which has been shown to be the dose-limiting tissue of RAIT (22, 34–37). Whereas we did observe a greater %ID/g $^{111}$In in the bone, our dosimetry estimates at the MTD of $^{90}$Y-DOTA-cPAM4 show that the amount of absorbed radiation dose would be similar to the amount that would be delivered at the MTD of $^{131}$I-cPAM4 (429 cGy versus 494 cGy, respectively).

Calculations on theoretical tumor models have suggested that for large tumors (as is the usual clinical presentation of pancreatic cancer), $^{90}$Y-labeled MAbs would achieve a higher therapeutic effect in comparison with $^{131}$I-labeled MAbs (38). Supporting this, we found that when administered at their respective MTDs, the $^{90}$Y-DOTA-cPAM4-treated mice exhibited a longer period and greater degree of antitumor response than mice that had received $^{131}$I-cPAM4. The increased antitumor effects provided by $^{90}$Y-DOTA-cPAM4 translated into a significantly longer survival time and cure for approximately one-half of the mice. Similar results were also noted at the lower doses of $^{90}$Y-labeled cPAM4 (representing as little as 67% of the MTD).

One of the main antitumor effects of RAIT is at the tumor vascular level (39–41). In a previous study, $^{131}$I-PAM4 RAIT was found to cause significant suppression of tumor vascular permeability in 1.0-g CaPan1 tumors at radiation doses of 3000 cGy (41). Even at the lowest doses administered in the current study (130 μCi for $^{90}$Y and 350 μCi for $^{131}$I), we delivered in excess of 4000 cGy to the tumors. To date, the exact mechanism(s) by which RAIT perturbs the intratumoral vasculature has not been fully elucidated. There is some evidence that the damage caused to the blood vessel is an indirect result via a tumoricidal response rather than direct radiation damage to the vessel itself (40). It may be that a higher percentage of tumor cells are killed with the $^{90}$Y-cPAM4 with a net result of causing a greater degree of damage to existing blood vessels (suppres-
sion of vascular permeability) as well as having an angiogenic effect. Additional studies need to be done to better understand how 90 Y-delivered radiation effect these and other aspects of tumor physiology.

On the basis of the biodistribution data, we estimated that the CaPan1 tumor in both cases would receive approximately the same absorbed radiation dose (~8000 cGy). The clear superiority of 90 Y over 131 I for PAM4-directed RAIT suggested that factors other then total absorbed tumor dose need to be considered when assessing the efficacy of RAIT. In this respect an important issue affecting the outcome of RAIT may be the heterogeneous distribution of intratumoral radiation dose. The choice of radioisotope may, thus, be critical. For large, bulky tumors, the relatively short pathlength for 131 I β emissions results in a heterogeneous dose distribution attributable to the nonuniform distribution of the antibody within solid tumors. On the other hand, 90 Y, having a longer pathlength of radiation emission, can provide for a more uniform dose distribution. That we could obtain similar antitumor effects at lower doses of 90 Y-DOTA-cPAM4 further suggests that dose distribution within the tumor may be as important, if not more important, than absolute absorbed dose.

In summary, we found that, at their respective MTDs, 90 Y-labeled cPAM4 had a significantly greater antitumor effect than 131 I-labeled cPAM4. One of the problems associated with RAIT of solid tumors is the relatively low tumor uptake of administered radiolabeled antibody in the human in comparison with that observed in mice (reviewed in Ref. 42). By using 90 Y-labeled cPAM4, we were able to demonstrate that this high-energy, residualizing radioisotope, further enhanced the antitumor effect of PAM4-directed RAIT in our tumor-model system, although both isotopes delivered a similar radiation dose to the tumor as a whole. This may allow for a similar enhancement of antitumor effects in patients, even when the relative uptake of antibody remains unchanged. Several approaches are being considered to further increase the antitumor efficacy of 90 Y-DOTA-cPAM4. First, the duration and extent of the antitumor response, even at the lower doses, suggests that multiple treatment cycles of 90 Y-labeled cPAM4 may provide an effective therapeutic for control of pancreatic cancer. Akin to this approach, others have shown that fractionated doses of RAIT can be more effective than single larger doses (43–46). This may be especially appropriate for 90 Y, because the bone marrow appears to rebound faster after 90 Y administration than after 131 I (30). Finally, we may be able to further increase tumor uptake of 90 Y by increasing the total PAM4 protein dose that is administered. We have previously demonstrated that increasing the PAM4 protein dose significantly increases tumor uptake of radiolabeled PAM4, as well as providing a more uniform distribution of the antibody within the tumor (3). Studies are now underway to determine whether these procedures will further enhance the therapeutic effect of 90 Y-DOTA-cPAM4 RAIT for pancreatic cancer.

REFERENCES


17. Gold, D. V., Cardillo, T., Vardi, Y., and Blumenthal, R. Radioimmu-


25. Pai-Scherf, L. H., Carrasquillo, J. A., Paik, C., Gansow, O., What-


28. Stein, R., Juweid, M., Mattes, M. J., and Goldenberg, D. M. Carci-


35. Vriesendorp, H. M., Quadri, S. M., Andersson, S. B., and Dicke, K. A. Hematotoxic side effects of radiolabeled immunoglobulin ther-


40. Blumenthal, R. D., Kashi, R., Sharkey, R. M., and Goldenberg, D. M. Quantitative and qualitative effects of experimental radioimmu-


42. Behr, T. M., Goldenberg, D. M., and Becker W. S. Radioimmuno-

43. Buchsbaum, D., Khazaie, M. B., Liu, T., Bright, S., Richardson, K., Jones, M., and Meredith, R. Fractionated radioimmunotherapy of human colon carcinoma xenografts with 131I-labeled monoclonal antibo-


Therapeutic Advantage of $^{90}$Yttrium- versus $^{131}$Iodine-labeled PAM4 Antibody in Experimental Pancreatic Cancer

Thomas M. Cardillo, Zhiliang Ying and David V. Gold


Updated version
Access the most recent version of this article at:
http://clincancerres.aacrjournals.org/content/7/10/3186

Cited articles
This article cites 38 articles, 14 of which you can access for free at:
http://clincancerres.aacrjournals.org/content/7/10/3186.full#ref-list-1

Citing articles
This article has been cited by 13 HighWire-hosted articles. Access the articles at:
http://clincancerres.aacrjournals.org/content/7/10/3186.full#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.